Pharmacokinetic simulation of biowaiver criteria: The effects of gastric emptying, dissolution, absorption and elimination rates

European Journal of Pharmaceutical Sciences

Volumn 30, Issue 2, 2007, Pages 155-166

  Kortejarvi H ^a   Urtti, A ^b   Yliperttula, M ^a  

^a Research and Development   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Bioavailability; Bioequivalency; Biopharmaceutics classification system; Biowaiver; Elimination rate; Formulation; Gastrointestinal tract; Pharmacokinetic simulation

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG SOLUBILITY; INTESTINE TRANSIT TIME; PRIORITY JOURNAL; SIMULATION; STOMACH EMPTYING;

AREA UNDER CURVE; CELL MEMBRANE PERMEABILITY; COMPUTER SIMULATION; GASTRIC EMPTYING; GASTROINTESTINAL TRACT; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 33846481265     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.10.011     Document Type: Article

References (27)

1. Amidon G.L., Lennernäs H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 3 (1995) 413-419
2. Barret S.B. Bioavailability and bioequivalence studies. In: Bonate P., and Howard D. (Eds). Pharmacokinetics in Drug Development: Clinical Study Design and Analysis (2004), American Association of Pharmaceutical Scientist, USA
3. Blume H.H., and Schug B.S. The biopharmaceutics classification system (BCS): class III drugs-better candidates for BA/BE waiver?. Eur. J. Pharm. Sci. 9 (1999) 117-121
4. Cheng C.-L., Yu L.X., Lee H.-L., Yang C.-Y., Lue C.-S., and Chou C.-H. Biowaiver extension potential to BCS class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablets. Eur. J. Pharm. Sci. 22 (2004) 297-304
5. Christensen F.N., Davis S.S., Hardy J.G., Taylor M.J., Whalley D.R., and Wilson C.G. The use of gamma scintigraphy to follow the gastrointestinal transit of pharmaceutical formulations. J. Pharm. Pharmacol. 37 (1985) 91-95
6. Corá L.A., Romeiro F.G., Américo M.F., Oliveira R.B., Baffa O., Stelzer M., and de Arruda J.R. Gastrointestinal transit and disintegration of enteric coated magnetic tablets assessed by ac biosusceptometry. Eur. J. Pharm. Sci. 27 (2006) 1-8
7. Coupe A.J., Davis S.S., and Wilding I.R. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm. Res. 8 3 (1991) 360-364
8. Davis S.S., Hardy J.G., and Fara J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut 27 (1986) 886-892
9. Dressman J.B., Amidon G.L., Reppas C., and Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15 1 (1998) 11-22
10. The European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP), 2000. Note for guidance on quality of modified release products: A: oral dosage forms, B: transdermal dosage forms (quality).
11. The European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP), 2002. Note for Guidance on the Investigation of Bioavailability and Bioequivalence.
12. Kaus L.C., Gillespie W.R., Hussain A.S., and Amidon G.L. The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. Pharm. Res. 16 2 (1999) 272-280
13. Kortejärvi H., Yliperttula M., Dressman J.B., Junginger H.E., Midha K.K., Shah V.P., and Barends D.M. Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. J. Pharm Sci. 94 8 (2005) 1617-1625
14. Meyer J.H. In: Johnson L.R. (Ed). Motility of the Stomach and Gastroduodenal Junction. Physiology of Gastrointestinal Tract. 2nd ed. (1987), Raven Press, New York 613-629
15. Oberle R.L., Chen T.-S., Iloyd C., Barnet J.L., Owyang C., Meyer J., and Amidon G.L. The influence of the interdigestive migrating myolectric complex in the gastric emptying of liquids. Gastroenterology 99 (1990) 1275-1282
16. Rinaki E., Dokoumetzidis A., and Macheras P. The mean dissolution time depends on the dose/solubility ratio. Pharm. Res. 20 3 (2003) 406-408
17. Rinaki E., Dokoumetzidis A., Valsami G., and Macheras P. Identification of biowaivers among class II drugs: theoretical justification and practical examples. Pharm. Res. 21 9 (2004) 1567-1572
18. Ritschel W.A., and Kearns G.L. In: Graubart J.I. (Ed). Handbook of Basic Pharmacokinetics, including Clinical Applications. 5th ed. (1999), American Pharmaceutical Association, Washington, DC 481-503
19. Schiller C., Fröhlich C.P., Giesmann T., Siegmund T., Mönnikes H., Hosten N., and Weitschies W. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol. Ther. 22 (2005) 971-979
20. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 1997. Guidance for Industry, extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations. Food and Drug Administration, Ed. Rockville, MD.
21. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2000. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Food and Drug Administration, Ed. Rockville, MD.
22. Vogelpoel H., Welink J., Amidon G.L., Junginger H.E., Midha K.K., Möller H., Olling M., Shah V.P., and Barends D.M. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J. Pharm. Sci. 93 8 (2004) 1945-1956
23. Wilding I.R., Behrens C., Tardif S.J., Wray H., Bias P., and Albrecht W. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Aliment Pharmacol. Ther. 17 (2003) 1153-1162
24. Wilson C.G., and Washington N. The stomach: its role in oral drug delivery. In: Rubinstein M.H. (Ed). Physiological Pharmaceutical: Biological Barriers to Drug Absorption (1989), Ellis Horwood, Chichester, UK 47-70
25. Yazdanian M., Briggs K., Jankovsky C., and Hawi A. The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm. Res. 21 2 (2004) 293-299
26. Yu L.X., Crison J.R., and Amidon G.L. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm. 140 (1996) 111-118
27. Yu L.X., Amidon G.L., Polli J.E., Zhao H., Mehta M.U., Conner D.P., Shah V.P., Lesko L.J., Chen M.L., Lee V.H.L., and Hussain A.S. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19 7 (2002) 921-925